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Lymphocyte and granulocyte function in zinc-treated and zinc-deficient
bemodialysis patients. Lymphocyte blast transformation and granulo-
cyte motility were studied in 20 clinically stable hemodialysis patients,
10 of whom were receiving 50mg of zinc (as zinc acetate) per day and 10
of whom were not. Plasma zinc concentration was significantly higher
in zinc-treated than in untreated patients (108 5 vs. 82 2 p.g/dI).
Mononuclear cell subpopulation analysis showed equivalent propor-
tions of T lymphocytes and monocytes in both groups, but B lympho-
cytes were reduced in untreated patients (10 0.7 vs 14 0.5%).
Lymphocyte blast transformations in response to nonspecific mitogens,
soluble antigen and mixed lymphocyte culture were not significantly
different in the two groups, nor was lymphocyte zinc concentration.
Zinc-treated patients showed significantly greater granulocyte respon-
siveness to zymosan-activated serum (21 1 vs. 14 2 p.), greater
chemokinetic activity (50 4 vs. 27 3 p.) and higher granulocyte zinc
concentration (114 6 vs. 47 2 p.g/106 cells) than untreated patients.
Granulocyte zinc correlated significantly with plasma zinc (r = 0.81, P
<0.001) and with granulocyte motility (r = 0.63, P 0.001). Moderate
zinc deficiency in hemodialysis patients does not result in abnormal
lymphocyte blast transformation in vitro, but it does result in granulo-
cyte zinc depletion and impaired granulocyte motility.
Fonctionnement lymphocytaire et granulocytaire chez des patients
bémodialysés traités par du zinc ou déficients en zinc. La transformation
blastique des lymphocytes et Ia motilité granulocytaire étaient étudié en
20 malades hémodialyses cliniquement stables, dont dix recevaient 50
mg de zinc par jour (sous forme d'acétate de zinc). La concentration
plasmatique en zinc était significativement plus élevée chez les sujets
traités par le zinc que chez les sujets non traités (108 5 contre 82 2
JLgldl). L'analyse des souspopulations cellulaires mononucléées a
montré des proportions equivalentes de lymphocytes T et de monocytes
dans les deux groupes, mais les lymphocytes B étaient diminués chez
les patients non traités (10 0,7 contre 14 0,5%). Les transforma-
tions blastiques lymphocytaires en réponse a des mitogénes non spéci-
fiques, a des antigènes solubles, et les cultures mixtes de lymphocytes
ne différaient pas significativement dans les deux groupes, pas plus que
Ia concentration en zinc lymphocytaire. Les malades traités par le zinc
avaient une reponse significativement plus forte de leurs granulocytes
au serum, active par du zymosan (21 1 contre 14 2 p.), une plus
grande activité chémotactique (50 4 contre 27 3 p.) et une plus forte
concentration de zinc granulocytaire (114 6 contre 47 2 p.g/106
cellules) par rapport aux sujets non traités. Le zinc granulocytaire était
significativement corrélé avec la concentration plasmatique du zinc (r =
0,81, P <0,001), et avec Ia motilitd granulocytaire (r = 0,63, P < 0,001).
Ainsi, une déficience modérée en zinc chez les patients hémodialysés
n'entraine pas d'anomalie de la transformation blastique des lympho-
cytes in vitro, mais s'accompagne d'une déplétion granulocytaire en
zinc, et d'un trouble de Ia motilité granulocytaire.
Patients with end-stage kidney disease often have manifesta-
tions of acquired defects in cellular immunity. They are usually
anergic [1—7], and many studies showing impaired lymphocyte
blastogenesis to nonspecific mitogens have been published [4,
6, 9—12]. In addition, abnormalities of granulocyte function,
especially chemotaxis, have been reported in renal failure
patients [5, 13—151. With the exception of anergy, however,
these observations have not been universal; some investigators
have reported normal lymphocyte [2—4, 16] or granulocyte [51
function in such patients.
Abnormal lymphocyte and granulocyte function have been
reported with zinc deficiency [17—23], and Mahajan et al have
demonstrated the vulnerability of renal failure patients to
physiologically significant zinc deficiency [24—26]. Therefore,
the possibility was considered that differences in results report-
ed for cellular immune function in uremia might be the result of
varying degrees of zinc deficiency among study populations. To
test this hypothesis, we studied lymphocyte blast transforma-
tion and granulocyte motility in zinc-treated and untreated
hemodialysis patients.
Methods
Subjects. Twenty male patients treated with chronic mainte-
nance hemodialysis for end-stage kidney disease were studied.
Ten patients received oral supplementation, 50 mg elemental
zinc/day as zinc acetate (group I), and 10 patients did not
receive zinc supplementation (group 2). All patients were
clinically stable and consumed their usual weight-maintaining
diets. All were treated by hernodialysis three times per week,
using the same type of dialysis software and hardware. Each
patient received daily multivitamins, ferrous sulfate and folic
acid supplementation routinely, and phosphate-binding antac-
ids, supplemental calcium and/or antihypertensive drugs in
doses appropriate for control of serum phosphate concentra-
tion, serum calcium concentration, and blood pressure,
respectively.
Six healthy subjects were recruited as a source of laboratory
control lymphocytes and granulocytes for cell function studies
along with cells from patients in groups I and 2. No subject was
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studied during an intercurrent illness or after any stressful
procedures, and none were taking drugs known to interfere with
granulocyte or lymphocyte function.
Isolation of cells. Venous blood (25 ml) was drawn into
syringes or test tubes containing preservative-free heparin.
Blood samples from patients were obtained prior to a regularly
scheduled dialysis treatment. Samples from laboratory control
subjects were obtained at random. Samples from at least one
patient in each group were obtained on collection days and
brought to the laboratory, having been labeled by code so that
the laboratory personnel had no knowledge of the patients'
names or treatment category.
Mononuclear cells were harvested by density gradient cen-
trifugation [27] using Ficoll-Paque (Pharmacia, Piscataway,
New Jersey), washed twice with RPMI 1640 media (GIBCO
Laboratories, Grand Island, New York) and suspended in
RPMI 1640/20% fetal calf serum (FCS) (GIBCO) in a concentra-
tion of 5 to 8 x 106 cells/mi. The cell suspension was cooled to
40 C and diluted with an equal volume of cold RPMI containing
20% FCS and 20% dimethyisulfoxide (DMSO) (Fisher, Fair-
lawn, New Jersey). One-milliliter aliquots containing 2.5 to 4 X
106 cells in Nunc tubes (Cryo-Med, Mt. Clemens, Michigan)
were frozen immediately to —90° C in a Cryo-Med Model 700
preprogrammed freezing system and stored in a liquid nitrogen
freezer in vapor phase [28], Mononuclear cells were stored by
cryopreservation in order to be able to study multiple samples
from treated and untreated patients, as well as healthy subjects,
on the same day. This was intended to minimize the effects of
day to day laboratory variables on the results of the blast
transformation studies [29, 30].
After removal of the mononuclear cell layer and excess
Ficoll-Paque, granulocytes were separated from the erythro-
cyte-granulocyte layer by dextran sedimentation of the erythro-
cytes. The granulocyte-rich supernate was mixed with Tris-
buffered isotonic ammonium chloride (14 mrvi ammonium chlo-
ride, 17 mrvi Tris, pH 7.2) and incubated at 37° C for 5 mm to
lyse residual erythrocytes, then washed twice in phosphate
buffered saline (PBS). Granulocytes were not frozen because of
their low recovery and viability in preliminary studies. There-
fore, they were studied on the days they were isolated.
Mononuclear subpopulation and blast transformation stud-
ies. Mononuclear cells were recovered from frozen storage by
thawing rapidly in a 37° C water bath with continuous shaking,
then placed in an ice-water bath. Then, the cells were diluted
slowly with RPMI/20% FCS at room temperature with continu-
ous gentle mixing and allowed to rest for 20 to 30 mm. The cells
were centrifuged 2 mm at 600 x g and resuspended in RPMI at a
final concentration of 1 x 106 viable cells/mi. The media was
supplemented with 2% FCS for 3-day cultures and 5% FCS for
5-day cultures. Recovery rates after cryopreservation were
from 60 to 95%. Viability was determined by trypan blue
exclusion and ranged from 85 to 95%. In preliminary studies, it
was determined that these freeze-thawing techniques did not
result in significant differences in subpopulations of mononucle-
ar cells or in blast transformation responses between aliquots of
cells from the same individuals studied after isolation versus
aliquots subjected to the freezing and thawing maneuvers used
for cryopreservation.
Mononuclear cell subpopuiation analyses were done quanti-
tating the proportions of cells forming nonimmune rosettes with
sheep erythrocytes (T lymphocytes), those bearing surface
immunogiobulins (B lymphocytes), and those ingesting latex
beads (monocytes), using standard techniques [31]. Monocytes
with surface immunoglobulin were subtracted from total sur-
facimmunoglobulins bearing cells to obtain the value for B
lymphocytes.
Lymphocyte blast transformation studies were carried out
using several different stimulants in a microassay system. These
stimulants included the nonspecific mitogens phytohemaggluti-
nm (PHA) (Difco Laboratories, Detroit, Michigan), pokeweed
mitogen (PWM) (Gibco), and concanavalin A (Pharmacia), a
specific antigen streptokinase-streptodornase (SKSD) (Lederle
Laboratories, Pearl River, New York) and allogeneic cell
surface antigens in one-way mixed lymphocyte cultures (MLC).
Mononuclear cells were cultured in microtiter plates in media
alone and with the above stimulants for either 3 days (PHA,
Con A) or 6 days (PWM, SKSD, MLC) at 37° C in a humidified
5% carbon dioxide atmosphere. PHA was added in final dilu-
tions of 1:1000 and 1:4000, Con A was added in final concentra-
tions of 2.5 and 5.0 p.g!ml, and PWM was added in final
dilutions of 1:50 and 1:200. SKSD was dialyzed against several
changes of PBS, then added in a final concentration of 5 p.g/mi.
The cells from two healthy subjects to be used as stimulating
cells in the one-way MLC were incubated with mitomycin C
(Sigma, St. Louis, MO), 25 p.g/l06 cells for 30 mm at 37° C,
washed three times with RPM!, suspended in FPMI 1640/5%
FCS, and added to microtiter plates in numbers equivalent to
those of the responding cells (l0 cells each). The cells from
each patient were tested in MLC with the same set of stimulat-
ing cells. The final concentrations of reagents and cell ratios
used in the study were those found to yield optimal blast
transformation results in preliminary studies. All cultures were
done in triplicate.
Eight hours prior to termination of the mononuclear cell
cultures, 0.5 p.Ci of 3H-thymidine (New England Nuclear,
Boston, Massachusetts; 6.7 Ci/mmoles) was added to each well.
Cultures were harvested onto glass fiber filter papers using a
mini-MASH (Microbiological Associates, Walkersville, Mary-
land). Filters were dried and counted in a liquid scintillation
spectrometer (Beckman, Fullerton, California). The counts per
minute (CPM) of nonstimulated cells were subtracted from the
CPM of stimulated cells to obtain the net enhancement of 3H-
thymidine incorporation by each stimulating agent.
Granulocyte motility. Stimulated granulocyte locomotion
with zymosan-activated serum (ZAS) and chemokinetic re-
sponses were studied in modified Boyden chambers [32, 33].
For studies of granulocyte responsiveness to complement-
derived factors, the lower chamber was filled with either RPM!
1640 media or RPMI/10% ZAS, using sera from healthy donors,
and the upper chamber with granulocyte suspension (3 x 106
cells/mi RPM! 1640). For chemokinetic studies, the lower
chamber was filled with media and the upper chamber with
granulocytes, 3 x 106/ml, in RPMI/lO% pooled normal human
serum. Upper and lower chambers were separated by a 3 p.m
millipore filter disc (Millipore, Bedford, Massachusetts). Dupli-
cate chambers for each maneuver were incubated for 30 mm at
37° C in a humidified 5% carbon dioxide atmosphere, following
which the discs were removed, stained, mounted and read by
the leading edge method [34]. Ten random fields were examined
in each filter. The distance of random migration into the filter
was subtracted from total migration to obtain net responses.
Plasma and cellular zinc. Plasma and cellular zinc concentra-
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Parameter comparisons
Patient
I
groupsa
2
49
36
24.8
5.2
1.4
82
13
3.5
9.0
4.5
3
5
1.9
0.6
0.1
6
2
0.2
0.2
0.5
Age, years
Duration of dialysis, month
Hematocrit, vol %
Total WBC count, x 103/pJ
Absolute lymphocyte count, x
BUN, mg/dl
Creatinine, mg/dl
Albumin, gIdi
Calcium, mgldl
Phosphorus, mg/dl
103/pJ
52 2
34 3
26.3 2.5
4.5 0.4
1.4 0.1
88 4
15 1
3.2 0.2
9.5 0.3
4.8 0.6
Numbers are mean SEM.
tions were determined by atomic absorption spectropho-
tometry, using methods described in detail elsewhere [35].
Analysis of data. Data analyses were begun after all studies
were completed and the results segregated according to wheth-
er each coded sample belonged to the zinc supplemented or
unsupplemented group. Differences in mean values for each
parameter studied were tested for statistical significance using
Student's t test for unpaired data. When evaJuating the relation-
ship between two parameters among subjects, determination of
the correlation coefficient was by regression analysis.
Results
There were no statistically significant differences between the
patients in groups 1 and 2 with regard to age, BUN, serum
creatinine, or other biochemical parameters (Table 1).
The results from our studies are summarized in Table 2. The
mean plasma zinc concentration was significantly higher in
patients receiving (108 5 j.g/dl) than in those not receiving (82
2 p.g/dl) supplementary zinc, but not significantly different
from the concentration found in healthy control subjects (113
3 p.tgldl) in our laboratories.
The proportions of mononuclear cells comprised of T lym-
phocytes and monocytes were not significantly different be-
tween the two groups of patients, but patients not receiving zinc
had a significantly lower percentage of B lymphocytes.
Lymphocyte responses to nonspecific stimulation with the
mitogens PHA, PWM, and Con A, to the soluble antigen
SKSD, and to allogeneic cell surface antigens in the one way
mixed lymphocyte culture, expressed as the amount of 3H-
thymidine incorporation during blast transformation studies,
were equivalent in zinc-treated and untreated patients. These
responses by cells from both groups of patients were not
significantly different from those by cells from healthy subjects
used as a source of stimulator cells in the MLC and as a control
for the cryopreservation and recovery procedures. (The means
SEM x l0 CPM!106 lymphocytes of healthy subjects' cells
were PHA — 69 5, PWM — 49 7, Con A —37 5, SKSD —
7.6 3.0, MLC — 4.1 0.9.)
The mean lymphocyte zinc concentration in the six patients
from each group tested was not significantly different between
the zinc-treated (138 15 p.g/106 cells) and untreated (132 13
p.g/106 cells) patients, and the concentration from neither pa-
tient group was significantly different from the mean in healthy
subjects (120 8 .g/106 cells) studied in our laboratories. No
significant correlations were found between lymphocyte zinc
Patient groups'6
1 2
Plasma zinc concentration, p.g/dl 108 5 82 2
Subpopulation analysis, %
T lymphocytes
B lymphocytes
Monocytes
Lymphocyte blast transformation, CPM x 103/106 lymphocytes
Phytohemagglutinin (PHA)
Pokeweed mitogen (PWM)
Conconavalin A (Con A)
Streptokinase/streptodornase
(SKSD)
One-way mixed lymphocyte culture
(MLC)
Lymphocyte zinc concentration,
pg/106 cells 138 15 132 13
Granulocyte motility, microns
Random locomotion
Response to zymosan-activated
serume
Chemokinetic activity
Granulocyte zinc concentration,
p.g/106 cells 114 6 47 2
Numbers are mean SEM.
N = 10 in each group for each parameter except lymphocyte zinc
where N = 6 in each group.
Net movement after subtracting random locomotion.
d P 0.05.
P 0.01.
0.001.
concentration and any other laboratory or clinical parameter
among the patients in this study.
Random locomotion, the response to zymosan-activated nor-
mal human serum and the chemokinetic response to pooled
normal human serum were all significantly greater with granulo-
cytes from zinc-treated than from untreated patients. Stimulat-
ed granulocyte motility, but not random locomotion, in the
treated patients was, however, significantly lower than that
obtained with granulocytes obtained from healthy subjects
(random locomotion, 22 1; response to ZAS, 33 I p.;
chemokinetic response, 70 7 p.). Granulocyte zinc concentra-
tion was significantly greater in treated than in uutreated
patients. Furthermore, significant correlations were found be-
tween granulocyte zinc concentration and plasma zinc concen-
tration (r = 0.81, P < 0.001), response to ZAS (r = 0.63, P =
0.001), and chemokinetic response (r = 0.65, P = 0.001) but not
other laboratory or clinical parameters, among all patients in
this study. The granulocyte zinc concentration in treated pa-
tients (114 6 p.g/l06 cells) was not significantly different from
that in healthy subjects (108 4 p.g/106 cells) studied in our
laboratories.
Discussion
Experimentally and clinically induced zinc deficiency has
been associated with abnormal lymphocyte function in vitro
Table 1. Comparison of clinical and laboratory parameters in the zinc-
treated (group 1) and untreated (group 2) patients
Table 2. Plasma zinc concentration, mononuclear cell subpopulations,
lymphocyte responsiveness, granulocyte motility and leukocyte zinc
concentrations in the treated (group 1) and untreated (group 2)
patients
58 3
14 0.5
8 0.5
57 2
10 0.7
10 0.6
69
40 5
34 5
4.4 1.8
79
41 4
39 6
2.1 0.6
7.9 2.4 3.5 0.5
21 2 18 Id
21 1 14 2
50 4 27 31
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and impaired cellular immunity in vivo, and zinc administration
has been reported to correct such disturbances in cell function
[17—22, 36—42]. Because patients with end-stage renal disease
appear vulnerable to the development of zinc deficiency [24—
26], the studies of lymphocyte function in hemodialysis patients
reported here were undertaken to determine whether or not
zinc deficiency might account for the impaired lymphocyte
blast transformation reported in some [4, 6, 9—12], but not all
[2—4, 16], patients with chronic renal failure. In this study, blast
transformation in response to nonspecific mitogens (PHA,
PWM, and Con A), to a specific antigen (SKSD), and to
allogeneic cell surface antigens (one-way MLC) by lympho-
cytes from patients with moderate zinc deficiency was found to
be equivalent to that by lymphocytes from zinc-treated patients
and from healthy subjects serving as laboratory controls.
These results appear to conflict with those of Antoniou,
Elliott, and Shaihoub [44], who reported profound hyporespon-
siveness to PHA of lymphocytes from four hemodialysis pa-
tients not receiving zinc supplements compared to four hemodi-
alysis patients receiving zinc supplementation. The reason for
this discrepancy is not apparent, but a larger group of patients
whose state of zinc nutrition was rather well defined was
studied here, and lymphocyte responsiveness was evaluated
more comprehensively. It is possible that the patients studied
by Antoniou, Elliott, and Shaihoub had a more severe degree of
zinc deficiency than those patients reported here.
Although the low plasma zinc concentrations in our patients
may not represent adequate criteria to say that they were in fact
zinc deficient, the presence of significantly decreased granulo-
cyte zinc concentrations represents strong confirmatory data
[24, 45]. In addition, renal failure patients with low plasma and
leukocyte zinc levels also have had impaired taste acuity and
impaired gonadal function, physiologic correlates of zinc defi-
ciency which were improved by zinc supplementation in pro-
spective, double-blind therapeutic trials [25, 26].
The failure to demonstrate impaired lymphocyte responsive-
ness in this study, which contrasts with the abnormal lympho-
cyte function reported in other clinical studies [41, 42], is likely
explained by differences in the degree of zinc deficiency among
subjects. Impaired PHA responsiveness by lymphocytes from a
patient with acquired zinc deficiency when plasma zinc was 41
p.g/dl, which corrected within 3 weeks of treatment, was
reported by Pekaret et al [42]. Oleske et al [41] reported
depressed lymphocyte responses to PHA, Con A, and PWM in
a patient with acrodermatitis enteropathica when plasma zinc
concentration was 22 pg/dl. Interestingly, PHA and Con A
responses were normal within 2 months of treatment with zinc
and remained normal even when the plasma zinc concentrations
(30 and 60 g/dl) were below the normal range for their
laboratory (70 to 120 pgIdl). In the studies referred to above,
plasma zinc concentrations at the time when abnormal lympho-
cyte function was noted were much lower than those observed
in our patients. No data regarding lymphocyte or leukocyte zinc
concentrations were available in those reports.
The lack of abnormal in vitro lymphocyte responsiveness in
this study does not exclude the possibility of impaired cellular
immunity in the patients. Although it was desired to test
cutaneous delayed hypersensitivity in the subjects of our study,
we found the patients resistant to the skin test procedure, due to
the frequency of needle punctures required for their dialysis
treatment. Reports in the literature, however, show return of or
increased intensity of cutaneous delayed hypersensitivity in
nonuremic subjects after treatment to correct zinc deficiency
[41, 42]. It is also possible that mononuclear cell function might
be compromised in moderately zinc deficient patients when
stressed by intercurrent illness, although the cells appear to
function normally when they are obtained from patients who
are clinically stable.
The explanation for and clinical meaning of the reduced
numbers of B lymphocytes in the zinc deficient patients are not
apparent from this study. We are currently investigating anti-
body responsiveness to antigenic challenge in zinc-treated and
untreated patients.
Granulocytes from zinc deficient patients showed significant-
ly impaired motility, both random and stimulated, in compari-
son with those from zinc-treated patients. Because only one
concentration of ZAS was used in these studies, it is not
possible to determine whether zinc deficiency resulted in defec-
tive locomotor responsiveness or a shift in dose-response
relationships between chemotactic factors and the granulocyte
membrane. Impaired random locomotion and chemokinetic
activity of the granulocytes as well, however, suggests a defect
in intrinsic locomotor capacity in affected cells. Additional
studies correlating functional responses with membrane and
contractile system biochemistry and ultrastructure will be re-
quired for further insights into the mechanisms by which zinc
deficiency impairs granulocyte motility.
Although granulocytes from zinc-treated patients showed
significantly greater locomotor responsiveness than untreated
patients, motility was significantly lower than that of the
nonuremic granulocytes. Impaired granulocyte chemotaxis in
chronic renal failure has been reported by many investigators
[5, 13—15] but not by all [5]. Normal human serum was
deliberately used in our studies to avoid the additional variable
of the presence of chemotactic inhibitors in uremic plasma [46—
48]. The hemodialysis patients in this study, therefore, mani-
fested impaired granulocyte motility, in some way related to
uremia but persisting in the absence of uremic plasma, which
was markedly aggravated by zinc deficiency.
Granulocyte zinc concentration was significantly lower in
untreated patients' cells than in other subjects' cells. It is
presumed that the granulocytes are more vulnerable to zinc
deficiency than lymphocytes because of their more rapid turn-
over rate, and that more severe degrees of zinc deficiency may
be required to cause decreased lymphocyte zinc concentrations
and abnormal blast transformation. Alternatively, lymphocytes
may have more efficient mechanisms for the prevention of
cellular zinc deficiency as extracellular concentrations fall, or
lymphocyte zinc content may be preserved as a result of one or
more of the many biochemical derangements associated with
uremia.
The significant correlations between granulocyte motility and
both plasma and granulocyte zinc concentrations among all
patients supports a pathophysiologic relationship between the
severity of impaired granulocyte locomotor response and zinc
deficiency in these patients. Abnormal granulocyte chemotaxis,
corrected by zinc replacement, has been reported by others in
nonuremic patients [40].
It is concluded from this study that moderate zinc deficiency
in otherwise clinically stable hemodialysis patients results in
abnormal granulocyte zinc concentration and further impairs
granulocyte motility in these patients. Lymphocyte zinc con-
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centration and blast transformation in vitro are well preserved
in such patients. The state of zinc nutrition should be consid-
ered in patients participating in studies of leukocyte function,
and in those experiencing recurrent or severe bacterial
infections.
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